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ABSTRACT 
Objective: The main objective was to develop simple, cost-effective, rapid and selective spectrophotometric methods for the determination of 
atorvastatin calcium and pitavastatin calcium in pure and pharmaceutical formulations using acid dyes like bromothymol blue, bromocresol purple 
and bromocresol green and also in human urine samples.  
Methods: The developed methods were based on the formation of ion-pair complexes between statin drugs and acid dyes after studying the 
optimization conditions. The association constants of the developed ion-pair complexes were evaluated using Benesi–Hildebrand equation. The 
methods were validated according to ICH guidelines.  
Results: The formed ion-pair complexes showed maximum absorbance which was measured at 637 nm for both methods A and D, 601 nm, 606 nm 
for methods B and E and 631 nm for both methods C and F respectively with correlation coefficients 0.999. The analytical parameters and their 
effects in the developed methods were investigated. The ion-pair complexes were stable up to 24 h and showed good linearity. The molar 
absorptivity, Sandell sensitivity, detection, and quantification limits were also calculated. The stoichiometry ratio in all the cases was 1:2 by using 
Job’s method of continuous variation. The recovery studies again showed good results because co-formulated substances did not interfere for the 
determination of ATC and PTC in the developed methods.  
Conclusion: The developed methods were applicable for routine quality control analysis of ATC and PTC in pure and pharmaceutical dosage forms. 
Good results were obtained when the developed methods were applied in healthy human urine samples. 
Keywords: Pitavastatin calcium, Atorvastatin calcium, Acid dyes, Spectrophotometry, Ion-pair complex, Validation 




Atorvastatin calcium (ATC) is chemically [R-(R,R)]-2 (4-
fluorophenyl)-β,δ-dihydroxy-5(1-methylethyl)-3-phenyl-4-
(phenylamino)]-1H-pyrrole-1-heptonoic acid, calcium salt (2:1) with 
molar mass 1115.36 g/mol whereas pitavastatin calcium (PTC) is 
monocalcium (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-
quinolinyl]-3,5-dihydroxy-6-heptenoic acid with molar mass 880.98 
g/mol. The chemical structures of them are shown in the fig. 1. They 
are the statin drugs and are a potent inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase. They are used to 
reduce serum levels of LDL-cholesterol; apolipoprotein B and 
triglycerides and to increase serum levels of HDL-cholesterol in the 
treatment of hyperlipidemias and prevent of cardiovascular diseases 
















Fig. 1: Chemical structures of atorvastatin calcium (ATC) and pitavastatin calcium (PTC) 
 
The literature survey revealed several analytical methods for the 
determination of both ATC and PTC. Chloroform extractable ion-pair 
complexes of AT with BCG, AR, BPB at 618.7, 512.8, 596.4 nm [4] and 
1,2-dichloroethane extractable ion-pair complexes of statin drugs 
with Mo(V) thiocyanate [5], were reported. Colorimetric 
determination of ATC-green complex with ferric chloride, potassium 
ferricyanide at 787 nm [6], acetylation of ATC with p-
dimethylaminobenzaldehyde, sulphuric acid at 540 nm [7], a red-
colored charge-transfer complex of ATC with DDQ at 460 nm [8] 
have also been reported. In potentiometry, modified carbon paste 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 11, Issue 6, 2019 
Venkatachalam et al. 
Int J App Pharm, Vol 11, Issue 6, 2019, 171-180 
172 
ion-selective electrodes were developed in which ion-pair of ATC 
with 5,6-diaminouracil hydrochloride, picric acid methods were 
tested [9]. Oxidative coupling reaction of statin drugs with 3-methyl-
2-benzothiazolinone hydrazone hydrochloride monohydrate, Ce(IV) 
at 566 nm [10], pale green-colored species formed with potassium 
ferrocyanide, ferric chloride by statin drugs [11], Oxidation reactions 
of ATC and PTC with ferric chloride in o-phenanthroline, ferric 
chloride in 2,2’-bipyridyl, ferric chloride in potassium ferricyanide 
[12,13], purple colored complex of PTC with Sulpho-Phospho-
vanillin reagent at 414 nm [14], CTC with TCNQ in acetonitrile at 
843 nm by ATC and PTC [15], PTC reaction with H2O2 and KI 
liberating iodine which was measured at 630 nm [16], PTC reduction 
in acidic KMnO4
The reported methods suffered from various disadvantages like 
heating step, slow reaction, extraction step, multi-step reactions, 
tedious control of experimental variables and less sensitivity. From 
the literature survey, it was found that the developed methods 
weren’t reported. The aim of this study was to develop and validate 
an accurate, reproducible and sensitive spectrophotometric 
methods based on the formation of ion-pair complexes between 
ATC/PTC with sulphonphthalein dyes namely bromothymol blue 
(BTB), bromocresol green (BCG) and bromocresol purple (BCP) for 
determination of ATC and PTC. The developed methods were 
applied for its determination in pharmaceutical formulations and 
also in human urine samples with good accuracy and precision. 
These methods were economically cheap, time-saving and more 
sensitive compared to other reported spectrophotometric methods.  
 giving unreacted oxidant measured at 550 nm [17], 
chromatographic methods for PTC [18] were the various methods 
developed for the study of lipid-lowering drugs.  
MATERIALS AND METHODS 
Instrument 
Double beam UV-visible spectrophotometric measurements were 
done using an Aglient 8453 model with a diode array detector (DAD) 
in the range 190-1100 nm was used for all experiments. UV and 
visible spectra of reference and sample solutions were recorded in 1 
cm diameter quartz cells. 
Reagents and solvents 
Pharmaceutical grade atorvastatin calcium (ATC) (purity 99.8 %) 
and pitavastatin calcium with purity 99.5 % (PTC) were gifted from 
Orchid Pharmaceutics, India and Shasun Pharmaceuticals, India 
which was used as received. The following formulations were 
obtained from commercial local pharmacies in Chennai and 
subjected to analysis: Atorva containing 10 mg and pivasta 
containing 2 mg (Zydus Cardiva, India). Bromothymol blue (BTB), 
bromocresol purple (BCP) and bromocresol green (BCG) (Sisco 
Research Laboratories (SRL) Private Limited) were used without 
further purification. Dimethyl sulfoxide (DMSO), N, N-dimethyl 
formamide (DMF) and acetonitrile were of spectroscopy grade 
solvents purchased from Merck, India. 
Preparation of standard ATC and PTC solutions 
The standard solution of ATC was prepared by dissolving accurately 
weighed 0.01 g of pure ATC with DMSO and diluted with the same 
solvent in a 100 ml calibrated flask which was equivalent to 100 
µg/ml used for method A. This solution was further diluted to get the 
working concentration of 25 µg/ml used for both the methods B and 
C. The standard solution of PTC was prepared by dissolving 
accurately weighed 10 mg of API PTC with DMSO for method D and 
DMF for method E in a 100 ml volumetric flask to get the 
concentration in 100 µg/ml. The working solution required for 
method F was diluted stepwise to get the concentration in 25 µg/ml. 
These solutions were prepared daily. 
Preparation of different reagent solutions 
The solutions were prepared by dissolving accurately weighed 0.01 
g, 0.05 g of BTB (0.01 % and 0.05 % BTB), 0.01 g of BCP (0.01 % 
BCP) and 0.01 g, 0.05 g of BCG (0.01 % and 0.05 % BCG) in 100 ml 
volumetric flask containing DMSO. 0.01 g of BCP (0.01 % BCP) was 
also prepared in 100 ml containing acetonitrile. 0.005 % BCP and 
0.005 % BCG solutions were diluted from the above-prepared 
solutions. These solutions were stable for one week if kept in a 
refrigerator. 
General recommended procedures 
Method A-ATC: BTB ion-pair complex 
Varying aliquots of the standard 100 µg/ml ATC solution from 2.50 
ml to 3.25 ml were transferred to different 5 ml calibrated flasks 
using a micro burette and added 0.5 ml of 0.05 % BTB solution to 
each flask which was diluted up to the mark with DMSO. It was 
shaken well for getting the uniform concentration. The absorbance 
of the resulting colored complex was measured at 637 nm against 
the corresponding blank solution prepared in the same method 
without the addition of ATC. 
Method B-ATC: BCP ion-pair complex 
Different aliquots of 25 µg/ml ATC drug solutions (2.5 ml, 2.75 ml, 
3.0 ml…4.0 ml) were transferred to 5 ml volumetric flasks. To each 
flask, 0.5 ml of 0.005 % BCP solution was added and diluted up to 
the mark with DMSO. The content was shaken well for the uniform 
concentration. The absorbance of the resulting colored complex was 
measured at 606 nm against the corresponding blank solution. 
Method C-ATC: BCG ion-pair complex 
In a series of aliquots 0.75 ml, 1.00 ml, 1.50 ml. 4.00 ml of 25 µg/ml 
ATC solutions in 5 ml volumetric flasks, 1.0 ml of 0.005 % BCG was 
added and diluted up to the mark with DMSO. They were shaken 
well for the uniform concentration. The absorbance of the resulting 
colored complex was measured at 631 nm against the corresponding 
blank solution. 
Method D-PTC: BTB ion-pair complex 
Aliquots of different dilutions (1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 ml) of 
100 µg/ml PTC was transferred into a series of 5 ml volumetric 
flasks using a micro burette, then added 0.5 ml of 0.01 % BTB to 
each flask, diluted up to the mark with dimethyl sulphoxide and 
shaken well for uniform concentration. The absorbance of each 
solution was measured at 637 nm against the reagent blank 
prepared in a similar way without the addition of PTC. 
Method E-PTC: BCP ion-pair complex 
Aliquots of different dilutions (1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 and 4.5 
ml) of 100 µg/ml PTC were transferred into a series of 5 ml 
volumetric flasks using a microburette and 0.5 ml of 0.01 % BCP was 
added to each flask. They were diluted up to the mark with a 50:50 
ratio of dimethylformamide and acetonitrile and shaken well for 
uniform concentration. The absorbance of each solution was 
measured at 601 nm against a reagent blank prepared in a similar 
way without the addition of PTC. 
Method F-PTC: BCG ion-pair complex 
Aliquots of different dilutions (1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 ml) of 
25 µg/ml PTC solution were transferred into a series of 5 ml 
volumetric flasks using a micro burette and 1 ml of 0.01 % BCG 
solution was added to each flask. The mixture was diluted up to the 
mark with dimethyl sulphoxide and shaken well for uniform 
concentration. The absorbance of each solution was measured at 
631 nm against a reagent blank prepared in a similar way without 
the addition of PTC. 
In the developed methods, the linear graphs were drawn by plotting 
the absorbance versus concentrations of ATC or PTC. The 
concentration of unknown solutions was calculated by linear 
regression. 
Procedure for the analysis of ATC/PTC in tablet dosage forms 
Ten tablets, each containing 10 mg of ATC or 2 mg of PTC, were 
accurately weighted and crushed into a fine powder using mortar 
and pestle. A weight equivalent to 10 mg of the corresponding finely 
powdered drug tablet was transferred into 100 ml volumetric flask 
in DMSO for methods A-D, F and DMF for method E. The solutions 
were shaken thoroughly for about 20 min and diluted up to the mark 
with the respective solvents, again shaken well to get the uniform 
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concentration. The filtrate was filtered using a Whatman No. 42 filter 
paper. The first 10 ml portions of filtrate were rejected and a 
suitable aliquot of the filtrate containing 100 µg/ml ATC or PTC was 
tested for the respective analysis. For methods B, C and F, 25 µg/ml 
solutions were diluted from the standard solution of 100 µg/ml. 
Procedure for the selectivity study 
The selectivity was tested by both placebo blank analysis and 
recovery studies using the developed methods for ATC and PTC. 
Placebo blank, commonly employed excipients added to the 
formulations, consisting of lactose monohydrate, low substituted 
hydroxypropyl cellulose, hypromellose, magnesium 
aluminometasilicate, magnesium stearate, and film coating 
containing the inactive ingredients like hypromellose, titanium 
dioxide, triethyl citrate and colloidal anhydrous silica was prepared 
and then subjected to the selectivity analysis. A synthetic mixture 
was prepared by adding 10 mg of pure ATC or PTC to the above-
mentioned placebo blank and the mixture was homogenized. 
Following the same procedure for tablet analysis, the synthetic 
mixture solution was prepared and a suitable quantity was 
subjected to the analysis by the developed methods. 
Procedure for Job’s method of continuous variation 
The compositions of ATC/PTC and the reagents were determined by 
using Jobs methods of continuous variation. Equimolar solutions of 
both drugs and reagents in 1.86 × 10-4 M were prepared for methods 
A, D and E, whereas for methods B, C and F, 9.30 × 10-5
 
M were used. 
A series of solutions were prepared in which the volume of statin 
drugs and reagents was kept as 3 ml and diluted up to the mark in 5 
ml volumetric flask with the corresponding solvents. The various 
proportions (0:3, 0.5:2.5, 1:2, 1.5:1.5, 2:1, 2.5:0.5 and 3:0) were 




Fig. 2: Absorption spectra for methods (A-F) 
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Procedure for spiked human urine 
10 ml of ATC/PTC free urine, which was collected from healthy 
volunteers, was taken in a 125 ml separating funnel and it was spiked 
with 15 ml of an aqueous solution containing 10 mg of pure ATC or 2 mg 
of pure PTC. To this solution, 5 ml of liquid ammonia followed by 20 ml 
of ethyl acetate was added. The contents were shaken for 20 min. The 
aqueous layer was discarded and the organic layer was collected in a 
beaker containing anhydrous sodium sulfate to remove the moisture. 
The water-free organic layer was transferred into a dried beaker and 
evaporated on a hot water bath. The dry residue was dissolved in 100 ml 
calibrated flask containing DMSO for methods A-D, F and DMF for 
method E separately. The solutions required for methods B, C and F were 
diluted from the solution obtained above. All these resulting solutions 
were analyzed following the given developed procedures. 
Method validation 
All developed methods were validated by linearity, sensitivity, precision, 
accuracy, robustness, ruggedness, recovery studies, according to the 
International Conference on Harmonization (ICH) guidelines [19]. 
RESULTS AND DISCUSSION 
Absorption spectra 
The absorption spectra of the formed ion-pair complexes between 
ATC or PTC and each of BTB, BCP and BCG the  at 190-1100 nm 
against the corresponding reagent blank. The different colored ion-
pair complexes showed maximum absorbance at 637 nm for both 
ATC: BTB and PTC: BTB, 606 nm for ATC: BCP, 601 nm for PTC: BCP, 
631 nm for both ATC: BCG and PTC: BCG, which was shown in the 
fig. 2. In all cases, a bathochromic shift occurred, i.e., shifted towards 
the longer wavelength from the shorter wavelength. These reactions 
were rapidly occurring at room temperature. 
Optimization of reaction conditions 
Preliminary tests were carried out for the formation of colored ion-
pair complex, such as the effect of solvent nature, effect of reagent 
concentration, the effect of time and stability of the formed ion-pair 
complexes. 
Effect of solvent nature 
The first parameter which was carried out in the optimization of the 
reaction condition was the nature of the solvent. The reactions were 
carried out in DMSO, DMF, DCM, chloroform and acetonitrile. For 
methods A and D, DMSO showed the maximum wavelength at 637 
nm whereas for methods B, C and F, it was at 606 nm, 631 nm and 
631 nm. For method E, DMF: acetonitrile (1:1) showed the maximum 
absorbance at 601 nm. Therefore, DMSO, DMF and acetonitrile 
solvents were fixed for further investigation. 
Effect of reagent concentration 
The effect of the reagent’s concentration on the intensity of the color 
developed at selected wavelengths was studied by measuring the 
absorbance of solutions containing a fixed concentration of ATC and 
PTC (50 μg/ml for methods A, D; 15 µg/ml for methods B; 5 µg/ml 
for methods C; 30 µg/ml for methods E; 10 µg/ml for methods F) 
and different amounts of the respective reagents, 0.5 ml of 0.05 % 
BTB solution (method A), 0.5 ml of 0.005 % BCP (method B), 1 ml of 
0.005 % BCG (method C), 0.5 ml from 0.01 % BTB (method D), 0.5 
ml from 0.01 % BCP (method E) and 1.0 ml from 0.01 % BCG 
(method F) solutions were effective to produce maximum and 
reproducible color with minimum blank absorbance. 
Effect of time and temperature 
The effect of shaking time and temperature after the addition of 
reagents to drugs on the formation of the respective ion-pair 
complexes and its stability were studied by measuring the absorbance 
at increasing time and temperature intervals. The results showed that 
ion-pair complexes were formed almost instantaneously in all cases at 
room temperature (25±2 °C) even in 1.0 min shaking. The developed 
color complexes were stable for more than 24 h (i.e. no effect on the 
absorbance of the formed color complexes). 
Stoichiometry composition of ion-pair complexes 
The absorbance of forming ion-pair complexes in each composition 
was measured and plotted against the mole fraction of the drugs, 
which was shown in the fig. 3. The plot reached a maximum value at 
a molar ratio of ATC or PTC to reagents in the complexes was 
determined by applying Job’s method of continuous variations. In all 
cases, the plots reached a maximum value at a mole fraction of 0.3 
which indicated the formation of 1:2 ion-pair complexes. 
Association constants of ion-pair complexes 
The association constants for the formed ion-pair complexes 
between ATC or PTC and the reagents were determined by using 
Benesi–Hildebrand equation where [BTB], [BCP], [BCG], [ATC] and 
[PTC] were the total concentration of the respective reagents and 
statin drugs. Ac is the absorbance of the complex, εc is the molar 
absorptivity of the ion-pair complex, and K IP  is the association 
constant of the formed ion-pair complex. The values of K IP were 
obtained from the slope of lines by plotting [reagent]/Ac
 
 against 
1/[ATC] or 1/[PTC] for all the developed methods. All the obtained 
plots were linear as shown in fig. 4. 
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Fig. 3: Job’s methods for the developed methods (A-F) 
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Fig. 4: Benesi-hildebrand plots for the association constants of the developed ion-pair complexes 
 
Gibbs free energy (ΔG °) values were also computed from KIP values for 
the formed ion-pair complexes according to the relationship, ΔG° = −(RT) 
ln (KIP) where, KIP
 
 is the association constant of the formed ion-pair 
complex, R is the gas constant (8.314 J/mol K), and T is the temperature 
in Kelvin. Negative values of ΔG ° indicate that the reactions were 
spontaneous and thermodynamically favored, shown in table 2. 
Table 2: Association constants for the developed ion-pair complexes 
Parameters ATC: BTB ATC: BCP ATC: BCG PTC: BTB PTC: BCP PTC: BCG 
ΔG ‒ 5.35×10 ‒ 7.05×10-3 ‒ 7.41×10-2 ‒ 4.56 ×10-3 ‒ 8.33×10-3 ‒ 2.73×10-3 -2 
K 8.54 IP 1.33 19.53 6.23 28.25 1.1153 
E 1.9523 IP 2.0522 1.9709 1.9523 2.0692 1.9709 
I 3.5273 p 3.477 3.5884 3.5273 3.472 3.5884 
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Reaction mechanism 
The ion-pair complexes were formed via electrostatic interaction 
between nitrogen moiety in ATC or PTC and oxygen moiety in the 
sulphonic acid group of the reagents. 
Analytical characteristics of the developed methods 
Under the optimum experimental conditions, linear correlations 
were obtained between the absorbance and concentration of ATC or 
PTC in the range of 50-65 μg/ml for method A, 12.5-20 μg/ml for 
method B and 3.75-20 μg/ml for method C, 20-80 μg/ml for method 
D, 20-90 μg/ml for method E and 5-20 μg/ml for method F by the 
method of least squares. In all developed methods, regression 
coefficients were 0.999 which indicated that excellent linearity was 
experimentally proved and shown in the fig. 7. The calculated slope 
and intercept values for the calibration data were described in table 
3. Sensitivity parameters such as molar absorptivity and Sandell’s 































































































































Fig. 6: Mechanism of the formed ion-pair complexes between PTC and the reagents 
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Table 3: Summary of regression and analytical validation parameters 
Parameters Method-A Method-B Method-C Method-D Method-E Method-F 
λmax 637  max, nm 606 631 637 601 631 
Beer’s law limits, µg/ml 50-65 12.5-20 3.75-20 20-80 20-90 5-20 
Molar absorptivity (ε), L mol-1 cm 1.39 × 10-1 4.6 × 104 4.54 × 104 1.2 × 104 9.82 × 104 8.53 × 103 
Sandell sensitivity
4 
a, μg cm 8.01 × 10-2 2.40 × 10-8 2.45× 10-8 7.34 × 10-8 8.97 × 10-8 1.03 × 10-8 
Limit of detection, μg ml
-8 
9.30 -1 10.04 2.96 9.30 10.04 2.96 




−1.9506 −1.0689 0.1768 −0.0435 −0.0399 0.6041 
Slope (b) 0.0425 0.0949 0.0321 0.0142 0.0115 0.0668 
Correlation coefficient 0.9996 0.9999 0.9995 0.9996 0.9994 0.9999 
Standard deviation of intercept, a (Sa 0.028 ) 0.009 0.005 0.0065 0.0067 0.0019 
Standard deviation of Slope, b (Sb 0 ) 0.001 0 0.0001 0.0001 0.0001 
aLimit of determination as the weight in µg per ml of solution, which corresponds to an absorbance of A= 0.001 measured in a cuvette of cross-
sectional area 1 cm2 and l= 1 cm., b
 




Fig. 7: Calibration plots for methods (A-F) 
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Accuracy and precision  
Table 4 explained the intra-day (repeatability) and inter-day 
(intermediary) precision results as a percentage relative standard 
deviation (% RSD) and intra-day (on the same day) and inter-day (for 
five consecutive days) accuracy data as percent relative error (% RE) 
for the assay of statin drugs in pure form by the developed methods. 
The percentage RSD values were found to be ≤ 2.17 %, reflecting the 
usefulness of the methods in routine use, and % RE data was ≤ 0.96 % 
which also proofed the high accuracy and high precision results. 
 





Intra-day  Inter-day 
ATC/PTC founda % RSD 
(µg/ml) 
% REb ATC/PTC foundc a % RSD 
(µg/ml) 
% REb c 
Method-A 55.0 55.40 1.38 0.72 55.50 1.42 0.91 
57.5 58.02 1.62 0.77 58.22 1.68 0.62 
60.0 59.89 1.74 0.40 70.12 1.85 0.67 
Method-B 13.75 13.12 1.24 0.60 13.10 1.28 0.40 
16.25 16.20 1.51 0.48 16.26 1.58 0.64 
18.75 18.33 2.00 0.26 18.25 1.44 0.53 
Method-C 10.0 10.55 1.46 0.77 10.22 1.52 0.80 
12.5 12.54 1.60 0.66 12.63 1.68 0.55 
15.0 15.82 1.37 0.57 15.60 1.44 0.69 
Method-D 30.0 30.10 1.42 0.33 30.15 1.47 0.50 
50.0 50.10 1.59 0.20 50.12 1.61 0.24 
70.0 70.12 1.38 0.17 70.14 1.46 0.20 
Method-E 40.0 40.10 2.17 0.25 40.12 2.07 0.30 
60.0 60.08 1.76 0.13 60.10 1.30 0.16 
80.0 80.05 2.08 0.06 80.01 1.42 0.12 
Method-F 07.5 07.55 1.33 0.66 07.56 1.41 0.80 
12.5 12.59 1.48 0.72 12.62 1.52 0.96 
17.5 17.56 1.51 0.34 17.60 1.58 0.57 
aMean value of seven determinations, bRelative standard deviation (%), c
 
Robustness and ruggedness 
Relative error (%); ATC used for methods A, B and C; PTC used for methods 
D, E and F. 
Robustness were assessed by using the standard solutions at three 
different concentrations of the reagents (n=3) in±0.2 ml variations 
at room temperature (25±2 °C). In order to demonstrate the 
ruggedness, the developed methods were evaluated by three 
different analysts applying the same developed procedures and also 
with three different spectrophotometer instruments by a single 
analyst in two laboratories. The % RSD with the altered reagent 
concentration was<1.94 % in pure drug which indicated that the 
absorbance value remained and unaffected. Regarding the 
evaluation of the ruggedness of the methods, % RSD of the inter-
analysts were<2.09 %, whereas the inter-instrumental variation 
was<2.18 %. These low values of precision demonstrated the 
robustness and ruggedness of the developed methods shown in 
table 5. 
 
Table 5: Robustness and ruggedness studies 
Developed methods ATC/PTC taken (µg/ml)  Method robustness Method ruggedness 
% RSD (n=3)   Inter-analyst (n=3)  Inter-instrument (n=3) 
Method-A 55.0 1.38 1.68 1.62 
65.0 1.62 1.82 1.90 
75.0 1.74 1.85 1.93 
Method-B 13.75 1.24 1.54 1.78 
16.25 1.51 1.62 1.69 
18.75 1.38 1.74 1.88 
Method-C 10.0 1.46 1.63 1.68 
12.5 1.60 1.80 1.82 
15.0 1.37 1.89 1.81 
Method-D 30.0 1.53 1.52 1.65 
50.0 1.68 1.69 1.78 
70.0 1.84 1.73 1.85 
Method-E 40.0 1.68 2.09 2.18 
60.0 1.29 1.83 2.08 
80.0 1.89 1.78 1.98 
Method-F 07.5 1.60 1.63 1.59 
12.5 1.78 1.80 1.82 
17.5 1.94 1.89 1.84 
Volumes of reagents used were 0.4 and 0.6 ml for BTB and BCP; 0.8 and 1.2 ml for BCG. ATC used for methods A, B and C; PTC used for methods D, E and F. 
 
Tablet analysis 
The results of the selectivity study confirmed that the developed 
methods were accurate and precise, even in the presence of various 
excipients. The analysis of synthetic mixture gave the percent 
recoveries ranged from 99.51-101.85 with a standard deviation of 
0.91-1.83 in all the cases. From the results, it was clear that the 
inactive ingredients did not interfere with the analysis. For statistical 
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comparison of the results of tablet analysis obtained by the developed 
methods with the reference methods, student’s t-test for accuracy and 
F-test for precision were applied to the experimental results. The 
results in table 6 showed that the Student’s t-and F-values at 95 % 
confidence level did not exceed the tabulated values of 2.57 and 5.05, 
which again confirmed that there was a good agreement between the 
results obtained by the proposed methods and the reference method 
[10, 14] with respect to accuracy and precision. 
 
Table 6: Results of tablets analysis by the developed methods with the reference methods 
Tablet brand Nominal amount (mg) b Reference Method[10],c Found % (of nominal amount±SD)  a 
Developed methods 
Method-A Method-B Method-C 
Atorva 10 97.24±1.50 100.06±0.86 100.25±1.19 99.99±1.66 
      t=1.97 t=1.52 t=2.19 
      F=3.87 F=3.79 F=4.28 
Tablet brand Nominal amount (mg) b Reference Method[14] Method-D ,c Method-E Method-F 
Pitvasta  2 99.39±0.033 100.16±0.83 100.05±1.09 99.99±1.56 
      t= 1.88 t= 1,67 t=2.11 
      F=2.96 F=3.55 F=3.01 
aMean value of five determinations, bManufactured by Zydus Medica (ATC), Zydus Cardiva (PTC), India, c
 
Recovery studies 
Tabulated t-value at the 95% confidence, 
level for four degrees of freedom is 2.57, Tabulated F-value at the 95% confidence level for four degrees of freedom is 5.05 
Table 7 explained recovery studies to determine accuracy and validity 
of the developed methods were carried out by a standard addition 
method. The pre-analyzed powdered tablet was spiked with pure ATC 
or PTC at three concentration levels and the total was determined by 
the developed methods. Each determination was repeated in three 
times. The recovery in the percentage of the pure drug was calculated 
as [(C1-C2)/C3] × 100, where C1 is the total statin drug concentration 
found, C2 is statin drug concentration in the tablet taken and C3 
 
is the 
pure statin drug concentration added to the formulation. The percent 
recoveries of pure drugs ranged from 99.11-101.41 % with standard 
deviation of 1.08-1.92, indicated that the recovery was good and 
formulation did not interfere with the developed method. 
Table 7: Accuracy assay by recovery experiments 
Developed 
methods 
ATC/PTC in tablet 
(µg/ml) 






Method-A 40.0 15.0 55.20 101.33±1.68 
40.0 25.0 65.10 100.40±1.48 
40.0 35.0 74.80 99.42±1.24 
Method-B 3.0 2.00 5.02 101.00±1.22 
3.0 3.25 6.23 99.30±1.45 
3.0 4.50 7.51 100.22±1.38 
Method-C 4.0 2.25 6.23 99.11±1.64 
4.0 3.50 7.54 101.14±1.44 
4.0 4.65 8.76 100.21±1.23 
Method-D 20.0 10.0 29.92 99.20±1.63 
20.0 30.0 50.10 100.33±1.38 
20.0 50.0 70.60 101.20±1.19 
Method-E 30.0 10.0 39.98 99.80±1.72 
30.0 30.0 60.12 100.40±1.89 
30.0 50.0 80.70 101.40±1.92 
Method-F 4.0 3.5 7.52 100.57±1.55 
4.0 8.5 12.62 101.41±1.08 
4.0 13.5 17.48 99.85±1.59 
a
 
Validation of the developed methods in urine samples 
Mean values of five determinations; ATC used for methods A, B and C; PTC used for methods D, E and F. 
The developed methods were further extended to the in vitro 
determination of ATC and PTC in human urine samples in the developed 
linearity range. A known volume of statin drugs was spiked into the 
urine samples prior to the developed analysis. The results of analysis of 
urine were summarized in table 8. The mean recoveries were in the 
range of 99.27–100.96 %. The obtained results clearly showed that the 
biological medium did not interfere with the absorbance. Overall, the 
developed methods were satisfactorily accurate and precise. 
 
Table 8: Application of the developed spectrophotometric methods for the determination of ATC and PTC in urine samples 
Developed methods Volume added (μg/ml) Volume found (μg/ml) Recovery (%)a 
Method-A 60.0 60.05 100.08 
Method-B 15.0 14.89 99.27 
Method-C 12.5 12.62 100.96 
Method-D 50.0 50.10 100.20 
Method-E 60.0 59.85 99.75 
Method-F 12.5 12.45 99.60 
aMean values of three determinations 
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CONCLUSION 
The developed methods which established the feasibility of the use 
of visible spectroscopy using the three reagents BTB, BCP and BCG 
can be employed for the determination of atorvastatin calcium and 
pitavastatin calcium in pure and pharmaceutical dosage forms. The 
developed methods can be performed at room temperature and 
make use of simple reagents, economically cheap and less time 
consuming, which an ordinary analytical laboratory can afford. 
Moreover, the procedure does not involve any critical reaction 
conditions and no pH adjustment is required. The developed 
methods which can be used in routine analysis of statin drugs in 
quality control laboratories were statistically evaluated and results 
obtained are accurate, precise, sensitive and free from the 
interferences of other additives present in formulations. 
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